Clinical Trial Update: Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI) [Phase 2]

View source ↗

Summary

The NAOMI Phase II trial is evaluating neoadjuvant aromatase inhibitor therapy for estrogen receptor-positive breast cancer. The study is currently active but n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Snippet

Sponsor: Dartmouth-Hitchcock Medical Center | Conditions: Breast Cancer, ER Positive Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING